SPRAGUE JOHN M (Chief Financial Officer) sold 12.9% of their position (5.25K shares) of T2 BIOSYSTEMS, INC. on the open market
Open‑market sale worth $10.7K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 2/23/2021ACC: 0000899243-21-007774
Officer· Chief Financial Officer
Since Jul 2018
-5.25K
Net shares
Net seller
$10.7K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
10K acquired · 15.25K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+10K
Price / share
—
Trade value
—
% of position
32.5%
2/21/2021
30.73K→40.73K
Common Stock
Direct
Shares
−5.25K
Price / share
$2.04
Trade value
$10.71K
% of position
12.9%
2/23/2021
40.73K→35.48K
Total
Net shares
+4.75K
Net value
-$10.71K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 2/21/2021 | M · Option Exercise | +10K | — | — | 32.5% | 30.73K | 40.73K |
| Common Stock Direct | 2/23/2021 | S · Sale | −5.25K | $2.04 | $10.71K | 12.9% | 40.73K | 35.48K |
| Total | +4.75K | -$10.71K | ||||||
Derivative Transactions1
Restricted Stock Units
Direct
Converts to
Common Stock
10K shares
Shares
−10K
Strike price
Held after
10K
Exercisable
—
2/21/2021
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Restricted Stock Units Direct | Common Stock10K shares | 2/21/2021 | M · Option Exercise | −10K | — | 10K |